

6 September 2022

## Treatment for Lung Cancer

**In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:**

Information as available from RISOH (Regional Information System Oncology & Haematology) May to June 2022

• Afatinib	<5
• Alectinib	<5
• Atezolizumab monotherapy	<5
• Atezolizumab in combination	<5
• Bevacizumab	<5
• Brigatinib	<5
• Capmatenib	<5
• Ceritinib	<5
• Crizotinib	<5
• Dacomitinib	<5
• Dabrafenib with Trametinib	<5
• Docetaxel monotherapy	<5
• Durvalumab	<5
• Erlotinib	<5
• Gefitinib	<5
• Gemcitabine + Carboplatin	<5
• Nintedanib with Docetaxel	<5
• Nivolumab	<5
• Osimertinib	10
• Paclitaxel	<5
• Pembrolizumab monotherapy	<5
• Pembrolizumab in combination	7
• Pemetrexed with Carboplatin/Cisplatin	<5
• Tepotinib	<5
• Vinorelbine with Cisplatin/Carboplatin	<5
• Any other SACT	<5
• Palliative care only	Not available from RISOH

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.